Citizen Portal
Sign In

Get Full Government Meeting Transcripts, Videos, & Alerts Forever!

Get email alerts on the Employee Benefits topic

No spam. Unsubscribe anytime.

Special School District board votes to stop covering GLP‑1 weight‑loss drugs in employee plan

District of St. Louis County Board of Education · June 24, 2025
AI-Generated Content: All content on this page was generated by AI to highlight key points from the meeting. For complete details and context, we recommend watching the full video. so we can fix them.

Summary

The District of St. Louis County Board of Education voted 5–2 to discontinue coverage of GLP‑1 medications for the indication of weight loss effective Jan. 1, 2026, citing sharply higher than expected costs; board members said the decision could be revisited if prices or insurance coverage change.

The District of St. Louis County Board of Education voted to discontinue coverage of GLP‑1 medications for weight loss, with the change to take effect Jan. 1, 2026. The motion carried following debate and a roll‑call vote.

Board discussion summarized the district’s timeline on the issue: coverage began April 1, 2023 on a broker’s recommendation that estimated annual costs near $110,000; board members said the district’s actual cost for the first 12 months was approximately $1.9 million and that continued coverage at current rates could materially affect next year’s budget. Board members framed the motion as a decision to preserve funds for salaries and operating needs while leaving open the possibility of reconsideration if prices fall or insurers change coverage.

Supporters of the motion argued the budgetary impact was unsustainable at current cost levels; opponents urged caution because many employees report medical benefits from the medications. The recorded roll call listed five votes in favor and two opposed and the chair announced the motion carried.

The board clarified the vote applies only to coverage for the indication of weight loss; other medically indicated uses of GLP‑1 class drugs were not part of this action. Board members said the decision can be revisited if market conditions, insurer contracts or generic alternatives change.

The board did not identify a specific date for a follow‑up review; officials said they would rely on new cost and coverage information to determine whether the district should reconsider coverage in the future.